NDV-01 Delivers 76% Complete Response at 12 Months in High-Risk NMIBC—Favorable Safety and Durability Set Up Phase 3 Program
Strong 12-Month Results in High-Risk and BCG-Unresponsive Bladder Cancer Populations
Relmada Therapeutics (NASDAQ: RLMD) has reported robust interim Phase 2 data for its sustained-release NDV-01 therapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC). Among the 48 patients dosed, the study demonstrated a 76% complete response (CR) rate maintained at 12 months—a promising sign for durability. Even more notably, patients identified as BCG-unresponsive, considered among the hardest to treat, achieved an 80% CR rate at 12 months. At any evaluation time, the CR rate crossed 90% in both the overall and BCG-unresponsive groups.
Safety Profile Is Favorable with No Grade 3 Events or Treatment Discontinuations
The interim results reinforce NDV-01's potential to fill a critical treatment gap. Importantly, the trial observed no progression to muscle-invasive disease, no radical cystectomy, and no Grade 3 treatment-related adverse events among participants. Additionally, no patients discontinued due to adverse effects, supporting a favorable tolerability profile over 12 months.
Efficacy Snapshot: NDV-01 in NMIBC
| Population | CR Rate Anytime | CR Rate at 12 Months | 12-Mo KM Analysis | No. Treated |
|---|---|---|---|---|
| Overall | 95% (36/38) | 76% (19/25) | 83% | 48 |
| BCG-Unresponsive | 94% (16/17) | 80% (8/10) | 84% | 20 |
Adverse Events Are Mostly Mild and Transient
The safety overview is equally reassuring. Of patients receiving at least one dose, 63% experienced treatment-related adverse events—most commonly transient Grade 1 dysuria (uncomfortable urination, lasting less than 24 hours). Less common were mild asymptomatic positive urine cultures and hematuria, with no cases escalating to severe toxicity or requiring discontinuation.
Phase 3 RESCUE Program Will Target Unmet Needs in Second-Line and Adjuvant Treatment Settings
With these interim results, Relmada will advance NDV-01 into its pivotal Phase 3 RESCUE program, targeting two crucial pathways:
- Intermediate-Risk NMIBC (adjuvant therapy): Open-label, randomized trial against observation; currently no approved therapies address about 75,000 US patients per year.
- Second-Line BCG-Unresponsive NMIBC (with CIS): Single-arm trial for patients who failed frontline therapy and have limited options besides radical cystectomy.
Key endpoints will include disease-free survival, recurrence-free survival, and patient quality of life.
Key Upcoming Milestones for NDV-01
| Milestone | Expected Timing |
|---|---|
| US IND Clearance for NDV-01 | Mid-2026 |
| Initiate Phase 3 RESCUE Program | Mid-2026 |
| Initial 3-Month Phase 3 Data (BCG-Unresponsive NMIBC) | Year-End 2026 |
Market Context: High Medical Need and Broad Application Potential
NMIBC accounts for nearly 80% of all bladder cancer cases and can recur as often as 80% over five years. Despite this burden, treatment options—especially for intermediate-risk and BCG-unresponsive patients—are extremely limited. NDV-01’s administration is quick (under five minutes), requires no anesthesia, and is patent-protected through 2038, making it a potentially attractive option for both patients and providers.
Final Thoughts: Data Underscore Advancement into Late-Stage Trials
NDV-01’s combination of durable long-term response, robust efficacy in difficult-to-treat populations, and manageable side effects is rare in the NMIBC landscape. Investors and clinicians alike will be watching closely as Relmada moves toward Phase 3 pivotal studies in 2026. If these trends persist, NDV-01 could carve out a new standard of care for NMIBC patients lacking bladder-sparing therapies.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI